SCHEDULE: RA Capital Exits Astria Therapeutics Stake

RA Capital Management and its affiliates have fully divested their beneficial ownership in Astria Therapeutics, Inc. as of June 30, 2025.

Summary

• RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. (collectively, the "Reporting Persons") filed an Amendment No. 2 to Schedule 13G.
• As of June 30, 2025, the Reporting Persons beneficially own 0.00 shares of Astria Therapeutics, Inc. common stock.
• This represents 0.0% of the class of securities.
• The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.

Sentiment

Score: 3

Explanation: The complete divestment of shares by a major institutional investor like RA Capital Management indicates a lack of confidence or a strategic shift away from Astria Therapeutics, which is generally a negative signal for the company's stock performance.

Negatives

• RA Capital Management and its affiliates have fully divested their stake in Astria Therapeutics, reducing their beneficial ownership to 0.0% as of June 30, 2025.

Future Outlook

No forward-looking statements or guidance are provided regarding Astria Therapeutics, Inc.'s future performance or strategic direction.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

Industry Context

RA Capital Management is a prominent institutional investor specializing in the healthcare and life sciences sectors. Their complete divestment from Astria Therapeutics, Inc. could signal a strategic portfolio reallocation or a revised outlook on the company's prospects within the broader therapeutics industry.

Stakeholder Impact

• Shareholders: Potential negative impact on stock price due to the complete divestment by a significant institutional investor.

Key Dates

Recommendation

The complete divestment of shares by RA Capital Management, a prominent healthcare-focused institutional investor, suggests a loss of conviction in Astria Therapeutics' future prospects. Such a full exit by a sophisticated investor often precedes or accompanies negative developments, making a 'sell' recommendation prudent for existing shareholders and advising against new positions.

Keywords

Astria Therapeutics, RA Capital Management, Schedule 13G, Institutional Ownership, Divestment, Common Stock, Healthcare Fund